David Roblin, Chief Operating Officer and Director of
Scientific Translation for the Francis Crick Institute since 2014,
is to become Chief Operating Officer and President of Research
& Development for Summit Therapeutics, a biopharmaceutical
company that targets Duchenne muscular dystrophy (DMD) and C.
difficile infection.
David will be stepping down in June 2017 as Chief
Operating Officer and Director of Scientific Translation, but will
retain a role advising on translation - the process of turning
research discoveries into treatments that directly benefit lives
and the economy, one of the Crick's five strategic
missions.
David will be both a Senior Scientific Translation Fellow, in
which capacity he will advise the Executive Committee and Board on
commercial translation, and chair of the Crick's Translation
Advisory Board.
David joined the Crick in September 2014 after a senior career
in the pharmaceutical industry and, before that, five years
practising medicine. He led on establishing the operations of a new
institute and led the Crick through the completion of its state-of
the-art building in 2016 and migration into the building from four
sites.
Summit's lead Duchenne muscular dystrophy drug, called
ezutromid, is in a Phase 2 clinical trial in patients, while Summit
is also developing in collaboration with the University of Oxford a
pipeline of earlier stage Duchenne muscular dystrophy therapies.
Summit's new antibiotic to treat C. difficile infection, called
ridinilazole, has successfully shown clinical benefit in a Phase 2
trial in patients.
Sir Paul Nurse, Director and Chief Executive of the Francis
Crick Institute, said: 'David was a wonderful Chief Operating
Officer and Director of Scientific Translation for the Crick at
exactly the right time, and he has laid firm foundations for our
future.
'David will be hugely missed in his current role, but I am
pleased that he is to retain connections with us and we look
forward to harnessing his expertise and commitment to the Francis
Crick Institute in new ways.'
David said: 'The Crick is a special place and it has been an
honour to play a role in its formation. I look forward both to
joining Summit and to staying involved with the Crick in a
different capacity.'
The Crick will soon be launching a search for a new Chief
Operating Officer. Senior oversight of the translation agenda will
be taken over by Peter Ratcliffe, Clinical Research Director, with
Veronique Birault, Head of Translation, taking full operational
responsibility for translation activities.